首页 > 最新文献

Australian Prescriber最新文献

英文 中文
Amifampridine for Lambert-Eaton myasthenic syndrome. 阿米福哌啶治疗兰伯特-伊顿肌无力综合征。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-09-01 DOI: 10.18773/austprescr.2022.056
{"title":"Amifampridine for Lambert-Eaton myasthenic syndrome.","authors":"","doi":"10.18773/austprescr.2022.056","DOIUrl":"https://doi.org/10.18773/austprescr.2022.056","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/4e/austprescr-45-176.PMC9584795.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug management of autosomal dominant polycystic kidney disease. 常染色体显性多囊肾的药物治疗。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-10-04 DOI: 10.18773/austprescr.2022.052
Thiveya Theivendran, Alister Ramachandran, Gopi Rangan

Autosomal dominant polycystic kidney disease is the most common genetic kidney disease affecting adults. Approximately 60% of patients develop kidney failure by 60 years of age due to slowly expanding kidney cysts. A healthy lifestyle and rigorous control of blood pressure slow kidney cyst growth. These interventions can be effective in reducing progression to kidney failure and cardiovascular disease, especially if started in early adulthood. Tolvaptan, a vasopressin receptor antagonist, slows kidney cyst growth and the decline in the estimated glomerular filtration rate by 1 mL/minute/1.73 m2 per year. It is indicated in patients with chronic kidney disease who are at high risk of progression to kidney failure. Chronic kidney pain is common and can be managed with analgesics, and input from pain specialists if refractory.

常染色体显性多囊肾是影响成年人的最常见遗传性肾病。由于肾囊肿缓慢扩张，约 60% 的患者到 60 岁时会出现肾衰竭。健康的生活方式和严格的血压控制可减缓肾囊肿的生长。这些干预措施可以有效减少肾衰竭和心血管疾病的进展，尤其是在成年早期开始实施。托伐普坦是一种血管加压素受体拮抗剂，可减缓肾囊肿的生长，并使肾小球滤过率每年下降1毫升/分钟/1.73平方米。该药适用于极有可能发展为肾衰竭的慢性肾病患者。慢性肾脏疼痛很常见，可使用镇痛药进行控制，如果疼痛难忍，还可请疼痛专家提供帮助。
{"title":"Drug management of autosomal dominant polycystic kidney disease.","authors":"Thiveya Theivendran, Alister Ramachandran, Gopi Rangan","doi":"10.18773/austprescr.2022.052","DOIUrl":"10.18773/austprescr.2022.052","url":null,"abstract":"<p><p>Autosomal dominant polycystic kidney disease is the most common genetic kidney disease affecting adults. Approximately 60% of patients develop kidney failure by 60 years of age due to slowly expanding kidney cysts. A healthy lifestyle and rigorous control of blood pressure slow kidney cyst growth. These interventions can be effective in reducing progression to kidney failure and cardiovascular disease, especially if started in early adulthood. Tolvaptan, a vasopressin receptor antagonist, slows kidney cyst growth and the decline in the estimated glomerular filtration rate by 1 mL/minute/1.73 m2 per year. It is indicated in patients with chronic kidney disease who are at high risk of progression to kidney failure. Chronic kidney pain is common and can be managed with analgesics, and input from pain specialists if refractory.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2d/2d/austprescr-45-167.PMC9584797.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anifrolumab for systemic lupus erythematosus. 治疗系统性红斑狼疮的 Anifrolumab。
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-09-01 DOI: 10.18773/austprescr.2022.059
{"title":"Anifrolumab for systemic lupus erythematosus.","authors":"","doi":"10.18773/austprescr.2022.059","DOIUrl":"10.18773/austprescr.2022.059","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/51/austprescr-45-177.PMC9584796.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40705258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Somatrogon for growth hormone deficiency. 生长激素缺乏症的生长激素。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-09-01 DOI: 10.18773/austprescr.2022.061
{"title":"Somatrogon for growth hormone deficiency.","authors":"","doi":"10.18773/austprescr.2022.061","DOIUrl":"https://doi.org/10.18773/austprescr.2022.061","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/7f/austprescr-45-181.PMC9584794.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug treatment of cystic fibrosis. 囊性纤维化的药物治疗。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-10-04 DOI: 10.18773/austprescr.2022.063
Matthew Bruorton, Thomas Goddard

Cystic fibrosis is the most common life-limiting autosomal recessive condition in Australia. A defect in the cystic fibrosis transmembrane conductance regulator protein affects chloride transport across epithelial cells. Patients with cystic fibrosis produce thick sticky mucus. This causes problems in multiple organs, particularly the lungs. Cystic fibrosis modulator therapies can partially correct the underlying pathophysiology and improve chloride transport, thereby improving morbidity. Life expectancy is improving, so many patients are now developing chronic diseases associated with ageing. All health professionals should be aware that the cystic fibrosis modulator therapies are metabolised via cytochrome P450 pathways in the liver. There are therefore significant drug-drug interactions with medicines metabolised by the same pathways.

囊性纤维化是澳大利亚最常见的限制生命的常染色体隐性遗传病。囊性纤维化跨膜传导调节蛋白的缺陷影响氯离子在上皮细胞间的转运。囊性纤维化患者产生粘稠的粘液。这会导致多个器官出现问题，尤其是肺部。囊性纤维化调节剂治疗可以部分纠正潜在的病理生理并改善氯离子转运，从而降低发病率。预期寿命正在提高，因此许多患者现在患上了与衰老有关的慢性疾病。所有卫生专业人员都应该意识到，囊性纤维化调节剂疗法是通过肝脏中的细胞色素P450途径代谢的。因此，通过相同途径代谢的药物与药物之间存在显著的相互作用。
{"title":"Drug treatment of cystic fibrosis.","authors":"Matthew Bruorton,&nbsp;Thomas Goddard","doi":"10.18773/austprescr.2022.063","DOIUrl":"https://doi.org/10.18773/austprescr.2022.063","url":null,"abstract":"<p><p>Cystic fibrosis is the most common life-limiting autosomal recessive condition in Australia. A defect in the cystic fibrosis transmembrane conductance regulator protein affects chloride transport across epithelial cells. Patients with cystic fibrosis produce thick sticky mucus. This causes problems in multiple organs, particularly the lungs. Cystic fibrosis modulator therapies can partially correct the underlying pathophysiology and improve chloride transport, thereby improving morbidity. Life expectancy is improving, so many patients are now developing chronic diseases associated with ageing. All health professionals should be aware that the cystic fibrosis modulator therapies are metabolised via cytochrome P450 pathways in the liver. There are therefore significant drug-drug interactions with medicines metabolised by the same pathways.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/cf/austprescr-45-171.PMC9584790.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40705259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of empagliflozin in chronic lithium toxicity. 恩格列净在慢性锂中毒中的作用。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-10-04 DOI: 10.18773/austprescr.2022.062
Vicki Dyson
{"title":"Role of empagliflozin in chronic lithium toxicity.","authors":"Vicki Dyson","doi":"10.18773/austprescr.2022.062","DOIUrl":"https://doi.org/10.18773/austprescr.2022.062","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/96/austprescr-45-158.PMC9584789.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Erratum: Trifarotene for acne [Correction]. 勘误:三氟罗汀治疗痤疮[更正]。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-10-01 Epub Date: 2022-10-04 DOI: 10.18773/austprescr.2022.064

[This corrects the article DOI: 10.18773/austprescr.2021.033.].

[这更正了文章DOI: 10.18773/ austpresr .2021.033.]。
{"title":"Erratum: Trifarotene for acne [Correction].","authors":"","doi":"10.18773/austprescr.2022.064","DOIUrl":"https://doi.org/10.18773/austprescr.2022.064","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.18773/austprescr.2021.033.].</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/6f/austprescr-45-183b.PMC9584791.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40688208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better. 如何在控制良好的哮喘患者中减少哮喘预防药物的治疗-越多并不总是越好。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.033
Helen K Reddel, Gloria J Foxley, Sharon R Davis

Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.

预防哮喘吸入器的大多数益处是在低剂量时看到的。然而，许多澳大利亚患者吸入的皮质类固醇剂量高于控制哮喘所需的剂量。开出不必要的高剂量预防剂会增加患者产生不良反应的风险。它们也可能增加病人的自付费用。哮喘指南建议在成人哮喘控制好2 - 3个月，儿童哮喘控制好6个月后，考虑逐步减少预防剂治疗。降压过程应针对每位患者个体化。预防治疗不应完全停止。
{"title":"How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.","authors":"Helen K Reddel,&nbsp;Gloria J Foxley,&nbsp;Sharon R Davis","doi":"10.18773/austprescr.2022.033","DOIUrl":"https://doi.org/10.18773/austprescr.2022.033","url":null,"abstract":"<p><p>Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/f8/austprescr-45-125.PMC9427634.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40361740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Drospirenone and mood. 屈螺酮与情绪
IF 3.4 Q2 PHARMACOLOGY & PHARMACY
Australian Prescriber
Pub Date : 2022-08-01 DOI: 10.18773/austprescr.2022.048
Andrew Zuschmann
{"title":"Drospirenone and mood.","authors":"Andrew Zuschmann","doi":"10.18773/austprescr.2022.048","DOIUrl":"10.18773/austprescr.2022.048","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/09/austprescr-45-116.PMC9427626.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cabotegravir. Cabotegravir。
IF 2.7 Q3 Medicine
Australian Prescriber
Pub Date : 2022-08-01 Epub Date: 2022-07-07 DOI: 10.18773/austprescr.2022.039
{"title":"Cabotegravir.","authors":"","doi":"10.18773/austprescr.2022.039","DOIUrl":"https://doi.org/10.18773/austprescr.2022.039","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/71/austprescr-45-134.PMC9427628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Australian Prescriber
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1